ÀÇ·áÁø ã±â
¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú ¾È³»
[¹®ÀÇÀüÈ] 1577-9966
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
Á¾¾ç³»°ú
-
[SCI]
Investigating the feasibility of targeted next-generation sequencing to guide to the treatment of Head and Neck Squamous cell Carcinoma.
Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, Cho BC, Nam BH, Chun SH, Hong JH, Kwon JH, Choi JG, K
/ Investigating the feasibility of targeted next-generation sequencing to guide to the treatment of Head and Neck Squamous cell Carcinoma.
/
-
Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay:
/ Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay:
/ 170(1):69~76
/
-
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
/ Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer.
/ 9(7):1145~1151
/
-
Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane : PROCEED trial (KCSG BR 11-01)
/ Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane : PROCEED trial (KCSG BR 11-01)
/
-
Genome- wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
/ Genome- wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
/ 202007